Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed Form 6-K on January 7, 2026. The filing serves as a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material change disclosed is the cessation of securities, as indicated by Exhibit 99.1 titled "Notification of cessation of securities - ATH."
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document is a procedural notification incorporated by reference into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details and effective date of the securities cessation referenced in Exhibit 99.1.
- Confirm the impact of the cessation on the company's capital structure and outstanding share count.
- Review the referenced Registration Statements (S-8 and F-3) for context on the securities being ceased.